FDA OK's genetic predictor of breast cancer relapse
Agency says test has flaws but can aid in treatment decisions
The Food and Drug Administration yesterday approved a genetic test that, when conducted soon after a woman learns she has breast cancer, can predict the odds of the disease returning and worsening. (Full article: 503 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
